Company Overview - Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [1] Proposed Offering - Rhythm announced a proposed public offering of $150 million of its common stock, with an additional option for underwriters to purchase up to $22.5 million of shares [1][2] - The offering is subject to market conditions and customary closing conditions, with no assurance on completion or terms [2] Regulatory Compliance - The offering is made under a shelf registration statement on Form S-3, which became effective on March 2, 2023 [3] - A preliminary prospectus supplement will be filed with the SEC and available on their website [3] Contact Information - Investor relations contact is David Connolly, Head of Investor Relations and Corporate Communications, reachable at 857-264-4280 [6]

Core Viewpoint - Ten-League International Holdings Limited successfully closed its initial public offering, raising a total of US$6,431,360 by offering 2,240,000 ordinary shares at a price of US$4.00 per share, with trading commencing on the Nasdaq Capital Market under the ticker symbol "TLIH" [1][2]. Group 1: Offering Details - The offering consisted of 2,240,000 ordinary shares, with 1,607,840 shares offered by the Company and 632,160 shares by selling shareholders [1]. - The Company received gross proceeds of US$6,431,360 from the offering before deducting underwriting discounts and other expenses [1]. - Bancroft Capital, LLC acted as the sole underwriter for the offering, which was conducted on a firm commitment basis [2]. Group 2: Use of Proceeds - Proceeds from the offering will be allocated for several purposes, including expanding the Company's product offerings, improving automation processes, investing in equipment and technology, and pursuing strategic acquisitions [2]. - Additional uses of the proceeds include marketing and brand building, repayment of bank borrowing, and general working capital [2]. Group 3: Company Overview - Ten-League International Holdings Limited is a Singapore-based provider of turnkey project solutions, primarily engaged in the sales and rental of heavy equipment, as well as engineering consultancy services for various industries [5]. - The Company's equipment is categorized into four types: foundation equipment, hoist equipment, excavation equipment, and port machinery [5]. - The mission of the Company is to deliver high-quality equipment and value-added engineering solutions while continuously adapting to new technologies [5].

Singapore, July 08, 2025 (GLOBE NEWSWIRE) -- Delixy Holdings Limited (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares, par value US$0.000005 per share, (“Ordinary Shares”), 1,350,000 of which are being offered by the Company and 650,000 by the selling shareholders Mega Origin Holdings Limited (as to 325,000 Ordinary Shares) and Novel Majestic Limited ...

IPO Trends - Venture capital-backed companies are heading towards the lowest number of US IPOs in ten years [1]

Market Regulation & IPO - Shenzhen Stock Exchange urges brokers to expedite ChiNext board listing applications [1]

Emmvee Photovoltaic Power has submitted a draft prospectus with India’s markets regulator seeking to raise funds via an initial public offering https://t.co/AUaF9Snl3P ...

Singapore, July 03, 2025 (GLOBE NEWSWIRE) -- Origin Investment Corp I (the “Company”), a newly organized special purpose acquisition company, today announced the closing of its initial public offering (“IPO”) of 6,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share and one-half of one redeemable warrant. The units began trading on the Nasdaq Global Market (“Nasdaq”) on July 2, 2025 under the ticker symbol “ORIQU”. Each whole warrant entitles the holder ther ...

Group 1 - The Company, EQV Ventures Acquisition Corp. II, successfully closed its initial public offering (IPO) of 42,000,000 units, which was upsized from 35,000,000 units, at a price of $10.00 per unit, generating total gross proceeds of $460 million before deductions [1] - The Company's units began trading on the New York Stock Exchange (NYSE) under the ticker symbol "EVACU" on July 2, 2025 [2] - Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [3] Group 2 - BTIG, LLC acted as the sole book-running manager for the offering, and the offering was made only by means of a prospectus [4] - Registration statements related to these securities were filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 1, 2025 [4]

Selangor, Malaysia, July 03, 2025 (GLOBE NEWSWIRE) -- Empro Group Inc. (the “Company” or “EMPG”), a rising beauty and personal care brand headquartered in Malaysia, today announced the closing of its initial public offering (the "Offering") of 1,375,000 ordinary shares (the "Ordinary Shares") at an initial public offering price of $4.00 per share for total gross proceeds of approximately $5,500,000, before deducting underwriting discounts and other offering expenses. The Offering closed on July 3, 2025, and ...

PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an e ...